checkmate 743 | First-line nivolumab plus ipilimumab in unresectable m

Keyword	CPC	PCC	Volume	Score	Length of keyword
checkmate 743	0.47	0.5	3281	51	13
checkmate	0.53	0.7	4740	93	9
743	0.26	0.2	684	34	3

Keyword	CPC	PCC	Volume	Score
checkmate 743	1.43	0.5	8870	45
checkmate 743 trial	0.07	0.8	1938	78
checkmate 743 mesothelioma	1.5	0.4	5416	43
checkmate 743 update	0.73	0.5	9898	79
checkmate 743 study	1.27	0.6	246	85

Search Results related to checkmate 743 on Search Engine

First-line nivolumab plus ipilimumab in unresectable malignant ... - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/33485464/

WebJan 30, 2021 · First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 Jan 30;397 (10272):375-386. doi: 10.1016/S0140-6736 …

DA: 20 PA: 43 MOZ Rank: 79

First-line nivolumab plus ipilimumab in unresectable malignant …
thelancet.com

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2820%2932714-8/fulltext

WebJan 21, 2021 · In CheckMate 743, overall survival outcomes with nivolumab plus ipilimumab were similar in the subgroups with less than 1% and with 1% or higher PD-L1 expressions and better outcomes were seen with nivolumab plus ipilimumab than with chemotherapy at 2 years in both subgroups.

DA: 58 PA: 59 MOZ Rank: 35

First-line nivolumab plus ipilimumab versus ... - Annals of Oncology
annalsofoncology.org

https://www.annalsofoncology.org/article/S0923-7534(22)00083-7/fulltext

WebFeb 2, 2022 · In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up.

DA: 76 PA: 41 MOZ Rank: 99

First-line nivolumab plus ipilimumab versus chemotherapy in
nih.gov

https://pubmed.ncbi.nlm.nih.gov/35124183/

WebBackground: In the phase III CheckMate 743 study ( NCT02899299 ), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up.

DA: 58 PA: 97 MOZ Rank: 11

Checkmate 743: A phase 3, randomized, open-label trial of …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.TPS8581

WebMay 30, 2017 · CheckMate 743 (NCT02899299) is a phase 3 study that will evaluate the efficacy and safety of first-line nivo + ipi vs chemotherapy for MPM. Methods: Approximately 600 adult pts with unresectable MPM and ECOG performance status …

DA: 72 PA: 55 MOZ Rank: 37

First-line nivolumab plus ipilimumab versus chemotherapy for the
nih.gov

https://pubmed.ncbi.nlm.nih.gov/35367910/

WebFirst-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 2022 May:167:8-16. doi: 10.1016/j.lungcan.2022.03.012. Epub 2022 Mar 21. …

DA: 86 PA: 15 MOZ Rank: 14

First-line nivolumab plus ipilimumab versus chemotherapy in …
annalsofoncology.org

https://www.annalsofoncology.org/article/S0923-7534(22)00083-7/pdf

WebFeb 3, 2022 · Background: In the phase III CheckMate 743 study (NCT02899299), ﬁrst-line nivolumab plus ipilimumab signiﬁcantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up.

DA: 39 PA: 61 MOZ Rank: 95

First-line nivolumab plus ipilimumab in unresectable malignant …
thelancet.com

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32714-8/abstract

WebJan 21, 2021 · First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial - The Lancet. Articles | Volume 397, ISSUE 10272, P375-386, …

DA: 68 PA: 38 MOZ Rank: 78

Updated Efficacy and Safety Data From CheckMate 743 First …
ascopost.com

https://ascopost.com/news/february-2022/updated-efficacy-and-safety-data-from-checkmate-743-first-line-nivolumabipilimumab-vs-chemotherapy-for-unresectable-malignant-pleural-mesothelioma/

WebPosted: 2/14/2022 12:41:00 PM. Last Updated: 2/14/2022 12:55:57 PM. With a follow-up of at least 3 years, the results from the CheckMate 743 study represent the first long-term survival data in a phase III study evaluating first-line immune checkpoint inhibition in patients with unresectable malignant pleural mesothelioma.

DA: 29 PA: 42 MOZ Rank: 58

FDA approves nivolumab and ipilimumab for unresectable …
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma

WebEfficacy was investigated in CHECKMATE-743 (NCT02899299), a randomized, open-label trial in patients with unresectable malignant pleural mesothelioma and no prior anticancer therapy.

DA: 27 PA: 49 MOZ Rank: 29